organization · Reporting owner
Golden Seeds Cognition Therapeutics LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
COGNITION THERAPEUTICS INC
Report date September 27, 2022 · Filed September 29, 2022
Section 16 reporting ended · disclosed 2022-09-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-09-27 transaction · row 1
1 source rowRow 1 · 2022-09-27 · Other · Disposed 2,489,682 · Balance 0 F1: Golden Seeds Cognition Therapeutics, LLC distributed these shares to its members on a pro rata basis for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Golden Seeds Cognition Therapeutics, LLC distributed these shares to its members on a pro rata basis for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 27, 2022 Filed Sep 29, 2022 20:02 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | OtherCommon Stock | 2,489,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-020050 · form4.xml · nonDerivative · entry 1 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Golden Seeds Cognition Therapeutics, LLC distributed these shares to its members on a pro rata basis for no consideration. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSimple Agreement for Future Equity · Derivative | Not disclosed | $0.00 | $2,992,382.00 |
DisclosureSEC source: 0001104659-21-126904 · tm2130061-7_4seq1.xml · derivative · entry 13 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 311,706 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7 · derivative.exercise_date: The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7 · derivative.expiration_date: The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | OtherWarrant (right to buy) · Derivative | 12,276 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126904 · tm2130061-7_4seq1.xml · derivative · entry 12 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,276 shares Expires 2023-03-15 F6 · derivative.exercise_date: The warrant expires on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the issuer's IPO or (v) upon repayment of a promissory note issued in connection with the warrant. F6 · derivative.expiration_date: The warrant expires on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the issuer's IPO or (v) upon repayment of a promissory note issued in connection with the warrant. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 1,574,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-126904 · tm2130061-7_4seq1.xml · derivative · entry 11 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 486,742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F4 · derivative.exercise_date: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F4 · derivative.expiration_date: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSeries B Convertible Preferred Stock · Derivative | 4,004,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-126904 · tm2130061-7_4seq1.xml · derivative · entry 10 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,237,959 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F3 · derivative.exercise_date: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F3 · derivative.expiration_date: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 542,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-126904 · tm2130061-7_4seq1.xml · derivative · entry 9 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 167,721 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F2 · derivative.exercise_date: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F2 · derivative.expiration_date: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 884,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-126904 · tm2130061-7_4seq1.xml · derivative · entry 8 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 273,321 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F1 · derivative.exercise_date: The Series A-1 Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F1 · derivative.expiration_date: The Series A-1 Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 311,706 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126904 · tm2130061-7_4seq1.xml · nonDerivative · entry 7 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,489,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | SaleCommon Stock | 33.09 | $12.00 | $397.08 |
DisclosureSEC source: 0001104659-21-126904 · tm2130061-7_4seq1.xml · nonDerivative · entry 6 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,177,985 F5 · kind: On October 13, 2021, the reporting person exercised a warrant to purchase 12,276 shares of CGTX common stock for $0.032 per share. The reporting person paid the exercise price on a cashless basis, resulting in CGTX's withholding of 33.09 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 12,242 shares. The issuer paid cash to the reporting person in lieu of any fractional share amounts. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | OtherCommon Stock | 12,276 | $0.03 | $392.83 |
DisclosureSEC source: 0001104659-21-126904 · tm2130061-7_4seq1.xml · nonDerivative · entry 5 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,178,019 Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 486,742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126904 · tm2130061-7_4seq1.xml · nonDerivative · entry 4 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,165,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 1,237,959 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126904 · tm2130061-7_4seq1.xml · nonDerivative · entry 3 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,679,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 167,721 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126904 · tm2130061-7_4seq1.xml · nonDerivative · entry 2 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 273,321 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126904 · tm2130061-7_4seq1.xml · nonDerivative · entry 1 Golden Seeds Cognition Therapeutics LLC · CIK 0001884796 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.